Literature DB >> 23993726

Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Fadia Mayyas1, Karem H Alzoubi, David R Van Wagoner.   

Abstract

Atrial fibrillation (AF), the most common cardiac arrhythmia, is an electrocardiographic description of a condition with multiple and complex underlying mechanisms. Oxidative stress is an important driver of structural remodeling that creates a substrate for AF. Oxidant radicals may promote increase of atrial oxidative damage, electrical and structural remodeling, and atrial inflammation. AF and other cardiovascular morbidities activate angiotensin (Ang-II)-dependent and independent cascades. A key component of the renin-angiotensin-aldosterone system (RAAS) is the mineralocorticoid aldosterone. Recent studies provide evidence of myocardial aldosterone synthesis. Aldosterone promotes cardiac oxidative stress, inflammation and structural/electrical remodeling via multiple mechanisms. In HF patients, aldosterone production is enhanced. In patients and in experimental HF and AF models, aldosterone receptor antagonists have favorable influences on cardiac remodeling and oxidative stress. Therapeutic approaches that seek to reduce AF burden by modulating the aldosterone system are likely beneficial but underutilized.
© 2013.

Entities:  

Keywords:  Aldosterone; Aldosterone antagonist; Atrial fibrillation; Oxidative stress

Mesh:

Substances:

Year:  2013        PMID: 23993726      PMCID: PMC4062912          DOI: 10.1016/j.ijcard.2013.08.022

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  138 in total

1.  Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation.

Authors:  A Goette; P Hoffmanns; W Enayati; U Meltendorf; J C Geller; H U Klein
Journal:  Am J Cardiol       Date:  2001-10-15       Impact factor: 2.778

2.  Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes.

Authors:  E Harada; M Yoshimura; H Yasue; O Nakagawa; M Nakagawa; M Harada; Y Mizuno; M Nakayama; Y Shimasaki; T Ito; S Nakamura; K Kuwahara; Y Saito; K Nakao; H Ogawa
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

3.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

4.  Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling.

Authors:  Emanuel Raschi; Giuseppe Boriani; Fabrizio De Ponti
Journal:  Curr Drug Targets       Date:  2011-02       Impact factor: 3.465

5.  Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.

Authors:  Tomohito Ohtani; Miho Ohta; Kazuhiro Yamamoto; Toshiaki Mano; Yasushi Sakata; Mayu Nishio; Yasuharu Takeda; Junichi Yoshida; Takeshi Miwa; Mitsuhiro Okamoto; Tohru Masuyama; Yasuki Nonaka; Masatsugu Hori
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-10-05       Impact factor: 3.619

6.  Increased expression of P-selectin in patients with chronic atrial fibrillation.

Authors:  A Goette; A Ittenson; P Hoffmanns; S Reek; W Hartung; H Klein; S Ansorge; J C Geller
Journal:  Pacing Clin Electrophysiol       Date:  2000-11       Impact factor: 1.976

7.  Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes.

Authors:  T Morgera; A Di Lenarda; L Dreas; B Pinamonti; F Humar; R Bussani; F Silvestri; D Chersevani; F Camerini
Journal:  Am Heart J       Date:  1992-08       Impact factor: 4.749

8.  Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.

Authors:  Ulrik Dixen; Lasse Ravn; Christian Soeby-Rasmussen; Anders Wallin Paulsen; Jan Parner; Erik Frandsen; Gorm B Jensen
Journal:  Cardiology       Date:  2006-09-12       Impact factor: 1.869

9.  Atrial expression of endothelial nitric oxide synthase in patients with and without atrial fibrillation.

Authors:  Alicja Bukowska; Christoph Röcken; Michaela Erxleben; Friedrich-Wilhelm Röhl; Matthias Hammwöhner; Christof Huth; Matthias P A Ebert; Uwe Lendeckel; Andreas Goette
Journal:  Cardiovasc Pathol       Date:  2009-02-11       Impact factor: 2.185

10.  Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology.

Authors:  Gopal J Babu; Poornima Bhupathy; Cynthia A Carnes; George E Billman; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2007-05-18       Impact factor: 5.000

View more
  20 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

Review 3.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 4.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

5.  Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013.

Authors:  David R Van Wagoner; Jonathan P Piccini; Christine M Albert; Mark E Anderson; Emelia J Benjamin; Bianca Brundel; Robert M Califf; Hugh Calkins; Peng-Sheng Chen; Nipavan Chiamvimonvat; Dawood Darbar; Lee L Eckhardt; Patrick T Ellinor; Derek V Exner; Richard I Fogel; Anne M Gillis; Jeff Healey; Stefan H Hohnloser; Hooman Kamel; David A Lathrop; Gregory Y H Lip; Reena Mehra; Sanjiv M Narayan; Jeffrey Olgin; Douglas Packer; Nicholas S Peters; Dan M Roden; Heather M Ross; Robert Sheldon; Xander H T Wehrens
Journal:  Heart Rhythm       Date:  2014-11-18       Impact factor: 6.343

Review 6.  Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update.

Authors:  Alejandra Gutierrez; David R Van Wagoner
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

Review 7.  Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

Authors:  Hermann Haller; Anna Bertram; Klaus Stahl; Jan Menne
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 8.  Atrial Fibrillation and Its Association with Endocrine Disorders.

Authors:  Manjari Devidi; Avanija Buddam; Sunil Dacha; D Sudhaker Rao
Journal:  J Atr Fibrillation       Date:  2014-02-28

9.  Renal denervation suppresses atrial fibrillation in a model of renal impairment.

Authors:  Zhuo Liang; Xiang-min Shi; Li-feng Liu; Xin-pei Chen; Zhao-liang Shan; Kun Lin; Jian Li; Fu-kun Chen; Yan-guang Li; Hong-Yang Guo; Yu-tang Wang
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

10.  Establishment of a model of renal impairment with mild renal insufficiency associated with atrial fibrillation in canines.

Authors:  Zhuo Liang; Li-Feng Liu; Xin-Pei Chen; Xiang-Min Shi; Hong-Yang Guo; Kun Lin; Jian-Ping Guo; Zhao-Liang Shan; Yu-Tang Wang
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.